申请人:Goedecke Aktiengesellschaft
公开号:US04751228A1
公开(公告)日:1988-06-14
The present invention provides 1,6-naphthyridine derivatives of formula ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring or an unsubstituted or substituted condensed aromatic or heterocyclic ring system, R.sup.2 is a straight-chained or branched alkyl radical containing up to 4 carbon atoms, a benzyl radical or a straight-chained or branched, substituted or unsubstituted aminoalkyl radical containing up to 8 carbon atoms, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radical or an alkoxycarbonyl radical, in each case containing up to 4 carbon atoms, R.sup.4 is a straight-chained or branched hydrocarbon radical containing up to 21 carbon atoms, which can also contain oxygen, sulphur, nitrogen or halogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems, or is an amino, cyano, formyl, halogenomethyl or dihalomethyl radical and R.sup.5 is an alkoxycarbonyl radical or an unsubstituted or substituted carboxamide radical with, in each case, up to 21 carbon atoms which can also contain oxygen, sulphur or nitrogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems or is a carboxyl or cyano group as well as the pharmaceutically acceptable salts thereof. The compounds are useful for blood vessel diseases. The present invention also provides processes for the preparation of these 1,6-naphthyridine derivatives, pharmaceutical compositions containing them, and methods for using them.
本发明提供了公式##STR1##的1,6-萘啶衍生物,其中R.sup.1是未取代或取代的芳香或杂芳环,或未取代或取代的紧缩芳香或杂环环系统,R.sup.2是直链或支链烷基基团,含有最多4个碳原子,苄基基团或直链或支链,取代或未取代的氨基烷基基团,含有最多8个碳原子,R.sup.3是氢原子,直链或支链烷基基团或烷氧羰基基团,在每种情况下都含有最多4个碳原子,R.sup.4是直链或支链碳氢基团,含有最多21个碳原子,也可以含有氧,硫,氮或卤素原子,并且可以通过碳环或杂环环系统取代,或者是氨基,氰基,甲酰基,卤代甲基或二卤代甲基基团,R.sup.5是烷氧羰基基团或未取代或取代的具有最多21个碳原子的羧酰胺基团,也可以含有氧,硫或氮原子,并且可以通过碳环或杂环环系统取代,或者是羧基或氰基,以及其药学上可接受的盐。这些化合物对于血管疾病是有用的。本发明还提供了制备这些1,6-萘啶衍生物的方法,含有它们的制药组合物以及使用它们的方法。